Progyny Inc
NASDAQ:PGNY

  • LAST PRICE
    15.7500
  • TODAY'S CHANGE (%)
    0.3100 (2.0078%)
  • Bid / Lots
    15.9500/ 2
  • Ask / Lots
    16.5000/ 6
  • Open / Previous Close
    15.7100 / 15.4400
  • Day Range
    15.6200
    16.0200
  • 52 Week Range
    13.3900
    42.0800
  • Volume
    1,919,203

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 18, 2024

  • Nov 14, 2024

  • Nov 13, 2024

      Show headlines and story abstract

    • 1:24PM ET on Wednesday Nov 13, 2024 by Dow Jones
      Companies Mentioned: PGNY

      1324 ET - It is unlikely that the election contributed to Progyny's weaker-than-expected 3Q results, or that future politics will affect upcoming quarters. CEO Pete Anevski says on a call with analysts that "it's hard to say whether or not the election had any impact on utilization or not," adding there's no concrete evidence that it did. "I'd be guessing if I commented further," he says. And while reproductive rights were a hotly debated topic during the election, Anevski says fertility shouldn't be affected by future politics. "On both sides of the aisle, they talked about protecting fertility," he says. "And so, that's positive." Shares fall 19% after Progyny, which provides fertility care insurance coverage for employers, cut its FY outlook and guided for a downbeat 4Q. (connor.hart@wsj.com)

    • 1:08PM ET on Wednesday Nov 13, 2024 by Dow Jones
      Companies Mentioned: PGNY

      1308 ET - Progyny, which provides fertility care insurance coverage for employers, says people are still pursuing care at clinics, but they are taking longer to go from consultation to treatment. This slowdown contributed to a weaker-than-expected 3Q. "Once people are progressing, we're seeing them consume fewer average stimulation-related assisted reproductive technology cycles than we've historically seen, specifically for freeze-alls and egg freezing," CEO Pete Anevski says on a call with analysts. The reason for the slowdown isn't immediately clear, he adds, citing that members haven't been maxing out their benefits and clinics don't have backlogs. Currently, it is too early to tell if this trend will continue, causing the company to temper its FY and 4Q outlooks out of caution, Anevski says. Shares fall 19%. (connor.hart@wsj.com)

Peers Headlines